Brokerage firm Piper Jaffray Maintains its rating on CoLucid Pharmaceuticals Inc(NASDAQ:CLCD). In a research note issued to the investors, the brokerage major Raises the price-target to $49.00 per share. The shares have been rated Overweight. The rating by Piper Jaffray was issued on Sep 30, 2016.
In a different note, On Sep 6, 2016, Ladenburg Thalmann said it Maintains its rating on CoLucid Pharmaceuticals Inc. In the research note, the firm Raises the price-target to $23.00 per share. The shares have been rated ‘Buy’ by the firm.
CoLucid Pharmaceuticals Inc (CLCD) made into the market gainers list on Tuesdays trading session with the shares advancing 2.37% or 0.86 points. Due to strong positive momentum, the stock ended at $37.12, which is also near the day’s high of $37.5. The stock began the session at $36.41 and the volume stood at 3,44,907 shares. The 52-week high of the shares is $39.27 and the 52 week low is $3.6. The company has a current market capitalization of $569 M and it has 1,53,34,908 shares in outstanding.
CoLucid Pharmaceuticals Inc(CLCD) last announced its earnings results on Aug 10, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-1.06. Analysts had estimated an EPS of $-0.84.
Several Insider Transactions has been reported to the SEC. On Sep 16, 2016, Thomas P. Mathers (Chief Executive Officer) sold 6,000 shares at $23.54 per share price.Also, On Sep 13, 2016, A/s Novo (10% owner) purchased 100,000 shares at $20.00 per share price.On Sep 7, 2016, Linda C. Hogan (Head, Bus. Dev. and Strategy) sold 48,736 shares at $19.75 per share price, according to the Form-4 filing with the securities and exchange commission.
CoLucid Pharmaceuticals Inc. is a United States-based clinical-stage biopharmaceutical company that develops a product candidate Lasmiditan for the treatment of central nervous system (CNS) disorders. The Company develops oral Lasmiditan for the acute treatment of migraine headaches in adults and intravenous Lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. Its Lasmiditan is used for the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies. The Company has completed seven clinical studies for Lasmiditan including a TQTc study and a Phase IIb study treating a single migraine attack in around 391 patients.